Form 10-Q · Quarterly report
Insulet Corporation 10-Q, filed Aug 5, 2026
- Filed
- CIK
- 0001145197
- Accession no.
- 0001145197-26-000169
Summary
Insulet Corporation reported total revenue of $801.7 million for the quarter ended June 30, 2026, up 23.5% from a year earlier, as Omnipod product revenue rose 24.6% to $795.9 million. The company recorded $29.3 million in charges in the quarter and $41.0 million for the first half related to two voluntary medical device corrections over cannula tears, with estimated total costs of $60 million to $70 million.
Key points
- Insulet's Q2 2026 Omnipod product revenue rose 24.6% to $795.9 million, with U.S. revenue up 20.1% and international revenue up 35.5%.
- The company recorded $29.3 million in Q2 2026 charges and $41.0 million for the six months related to two voluntary medical device corrections, estimating total costs of $60 million to $70 million.
- Insulet expanded Omnipod 5 compatibility with Abbott's FreeStyle Libre 3 Plus in the U.S. in June 2026 and launched Omnipod 5 in Spain in July 2026.
- It enrolled the first participant in the EVOLVE pivotal study for a fully closed-loop automated insulin delivery system for type 2 diabetes, targeting a planned 510(k) submission in 2027.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion Overview Our mission is to transform the lives of people with diabetes. We are primarily engaged in the development, manufacture, and sale of our proprietary Omnipod product platform, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod platform primarily includes our most recent generation Omnipod 5 and its predecessor Omnipod DASH, which eliminate the need for multiple daily injections using syringes or insulin pens or the use of pump and tubing. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.